Introduction
============

RNase L, encoded by the *RNASEL* gene, is a ubiquitously expressed endoribonuclease.[@b1-ott-11-097] It is activated by dimerization, which occurs upon 2′--5′A binding, and results in cleavage of all RNAs in the cell. This can lead to activation of MDA5, an RNA helicase involved in the production of interferons.[@b2-ott-11-097] Beyond its antiviral activity, RNASEL contributes toward innate immunity and cell metabolism including inflammation, cell proliferation and differentiation, migration, apoptosis, and tumorigenesis.[@b3-ott-11-097]--[@b5-ott-11-097]

Several variations in RNASEL have been identified, of which the mutation at codon 462 is functionally distinct: the Arg-to-Gln variant has a threefold reduced enzyme activity, which could enhance virus susceptibility, impair the cellular stress response, diminish control of cellular RNA levels, or induce apoptosis.[@b6-ott-11-097]

Over the years, the rs486907 G/A polymorphism in the *RNASEL* gene has been studied to assess its association with risk of prostate cancer.[@b7-ott-11-097],[@b10-ott-11-097]--[@b13-ott-11-097] However, the results are inconsistent, which might be caused by the limitation of individual studies. To shed light on the associations between the *RNASEL* gene polymorphism and prostate cancer risk, we performed this meta-analysis of 16 case--control studies retrieved from 13 published papers.[@b7-ott-11-097]--[@b19-ott-11-097]

Methods
=======

Search strategy
---------------

We searched the PubMed, Embase, and Web of Science databases for papers published in the past 20 years from 1997 through to 2017, using the keywords "*RNASEL*", "cancer or carcinoma or tumor", and "polymorphism or variant". A search conducted with these terms yielded a total of 81 publications, of which 14 were finally selected. We also screened the referenced literature of the selected publications manually.

Inclusion and exclusion criteria
--------------------------------

Studies were required to fulfill the following inclusion criteria: they should 1) assess the correlation between prostate cancer risk and the RNASEL --1385G/A polymorphism, 2) be case--control studies, and 3) consider sufficient numbers of genotypes for cases and controls. Studies were excluded if they 1) included no control population, 2) did not report genotype frequency data, and 3) were publications using the same dataset.

Data extraction
---------------

Two authors independently extracted all data from the selected publications. These data included the first author's last name, year of publication, country of origin, ethnicity of the study population, total number of samples in case and control groups, numbers of each genotype in both case and control groups, *P*-value of Hardy--Weinberg equilibrium (HWE) of the control group, and genotyping method. Ethnicity was categorized as individuals of European descent and African or Asian, and control subgroups were population-based and hospital-based (HB).

Statistical analysis
--------------------

Based on genotype frequencies for cases and controls, crude odds ratio (OR) with 95% confidence interval (CI) was used to measure the strength of associations between the rs486907 polymorphism and prostate cancer risk. The statistical significance of the OR was determined with the *Z* test. The heterogeneity assumption among studies was evaluated using a *χ*^2^-based *Q* test. A *P*-value of \>0.10 for the *Q* test indicated a lack of heterogeneity among studies. If significant heterogeneity was detected, the DerSimonian--Laird random-effects model or the Mantel--Haenszel fixed-effects model was chosen for analysis.[@b20-ott-11-097],[@b21-ott-11-097] We investigated the relationship between the rs486907 genetic variant of the *RNASEL* gene and cancer risk by testing for the allelic contrast (G vs A), homozygote comparison (GG vs AA), heterozygote comparison (GG vs GA), and dominant genetic model (GG + GA vs AA). A sensitivity analysis was performed by omitting studies, one after the other, to assess the stability of results. The departure of frequencies of the RNASEL polymorphism from expectations under HWE was assessed by the Pearson's *χ*^2^ test, and the values of *P*\<0.05 were considered significant.[@b22-ott-11-097] Publication bias was investigated using Egger's linear regression method and Begg's funnel plots, where *P*\<0.05 was considered significant.[@b23-ott-11-097] All statistical tests for meta-analyses were performed using Stata software version 10.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Study characteristics
---------------------

Using various combinations of key terms, a total of 81 publication titles were identified from the PubMed, Embase, and Web of Science databases. As shown in [Figure 1](#f1-ott-11-097){ref-type="fig"}, 40 publications were excluded from the analysis after screening the abstracts. The full texts of the remaining papers were then evaluated, and 27 additional publications were excluded for the following reasons: duplications (10), meta-analyses or systematic reviews (1), publications dealing with other polymorphisms (16), and one publication having no case--control group. Finally, 13 publications including 16 case--control studies were chosen for our meta-analysis. The distribution of genotypes in all the control groups was in agreement with HWE. The genotyping methods used in the different studies that were a part of our meta-analysis included restrictive fragment length polymorphism polymerase chain reaction, TaqMan, Sequenom platform, and mass spectrometry-based genotyping analysis. Characteristics of the case--control studies included in this meta-analysis are shown in [Table 1](#t1-ott-11-097){ref-type="table"}.

Quantitative synthesis
----------------------

Results of the overall meta-analysis are shown in [Table 2](#t2-ott-11-097){ref-type="table"}. There was no positive association between this polymorphism and prostate cancer susceptibility ([Figure 2](#f2-ott-11-097){ref-type="fig"}). When stratified by ethnicity, we observed that the polymorphism was associated with a decreased prostate cancer risk in African-descent patients (GG/GA vs AA: OR =0.366, 95% CI =0.174--0.770, *P*~heterogeneity~ =0.095; GG vs AA: OR =0.370, 95% CI =0.176--0.783, *P*~heterogeneity~ =0.098; [Figure 3](#f3-ott-11-097){ref-type="fig"}). Analysis of the subgroups based on the source of control indicated that the polymorphism was associated with a decreased prostate cancer risk in HB controls (GG vs AA: OR =0.697, 95% CI =0.488--0.996, *P*~heterogeneity~ =0.000; GG + GA vs AA: OR =0.701, 95% CI =0.502--0.978, *P*~heterogeneity~ =0.001; [Figure 4](#f4-ott-11-097){ref-type="fig"}).

Bias diagnosis and sensitivity analysis
---------------------------------------

Egger's and Begg's tests were performed to assess publication bias. No proof of publication bias was found, except overall GG vs GA and GG/GA vs AA. A sensitivity analysis was performed to assess the influence of each study on the pooled OR by sequential removal of individual studies. Neither Begg's funnel plot nor Egger's test detected any obvious evidence of publication bias in the subgroup analyses for all genetic models. [Figure 5](#f5-ott-11-097){ref-type="fig"} shows the funnel plot for GG vs AA of prostate cancer in Africans.

Discussion
==========

Under normal conditions, RNASEL has tumor-suppressive and antiproliferative functions, although the common rs486907 variant of *RNASEL* gene has been associated with risk of a number of cancers.[@b21-ott-11-097]--[@b24-ott-11-097] Up to now, many molecular epidemiological studies were performed to assess the associations of this polymorphism with prostate cancer risk. In a large American series, Casey et al observed statistically significant ORs for prostate cancer patients carrying the RNASEL variant G-allele (GG vs AA: OR =2.12, 95% CI =1.19--3.78; GA vs AA: OR =1.46, 95% CI =0.65--1.19).[@b6-ott-11-097] In 2002, Rökman et al analyzed 233 unselected patients with prostate cancer and 176 unaffected sibling controls from Finland, and found that the Gln/Gln variant was more frequent in 66 patients with hereditary prostate cancer than in 176 controls, but was not more frequent in unselected 167 patients with prostate cancer compared with controls.[@b26-ott-11-097] By contrast, Wang et al found that homozygosity for the Arg variant was less frequent in 493 controls compared with 433 familial prostate cancer patients from the USA.[@b17-ott-11-097] Following these studies, two more papers on the association involving larger sample sizes were published,[@b24-ott-11-097],[@b25-ott-11-097] which indicated that the rs486907 polymorphism in the RNASEL gene is not associated with an increased risk of developing prostate cancer. In order to verify this association, our meta-analysis combined data from 7,602 patients with prostate cancer and 7,108 controls, and revealed that the rs486907 polymorphism was not associated with prostate cancer risk. When stratified by ethnicity, we found that the rs486907 variant was associated with a decreased cancer risk in Africans (GG vs AA: OR =0.370, 95% CI =0.176--0.783; GG/GA vs AA: OR =0.366, 95% CI =0.174--0.770). Therefore, the variant G-allele might be a protective factor against prostate cancer in African-descent individuals.

Although we expended considerable efforts in identifying as many associations between the *RNASEL* gene polymorphism and cancer risk as possible, our study still suffers from some inherent limitations. First, the different genotyping strategies may contribute to bias in the analysis. Second, factors associated with gene--gene and gene--environment interactions were poorly represented. It is possible that specific environmental and lifestyle factors such as age, sun exposure, smoking, drinking, and family history could alter the associations between the gene polymorphism and prostate cancer risk. Therefore, it is necessary to determine the roles of specific environmental factors and lifestyles. Third, we were unable to analyze how the different developmental stages of prostate cancer are associated with the RNASEL polymorphism.

In conclusion, our present meta-analysis suggests that the rs486907 polymorphism in the *RNASEL* gene may not be associated with prostate cancer risk. However, the variant G allele might be a protective factor against prostate cancer in African-descent individuals. Further studies based on larger sample sizes and considering additional gene--environment interactions should be conducted in the future.
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![Forest plot of the rs486907 polymorphism and prostate cancer risk: GG vs AA for total.\
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![Forest plot of the rs486907 polymorphism and prostate cancer risk: GG + GA vs AA for Africans.\
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![Forest plot of the rs486907 polymorphism and prostate cancer risk in hospital-based controls: GG + GA vs AA.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](ott-11-097Fig4){#f4-ott-11-097}

![Begg's funnel plot for publication bias test of prostate cancer (GG vs AA).\
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###### 

Main characteristics of included studies in the meta-analysis

  Studies                                Year   Country   Ethnicity   Cancer type       Case/control   SOC   Genotype assay      Case   Control                           
  -------------------------------------- ------ --------- ----------- ----------------- -------------- ----- ------------------- ------ --------- ----- ----- ----- ----- -------
  Alvarez-Cubero et al[@b7-ott-11-097]   2016   Spain     European    Prostate cancer   141/145        HB    RFLP-PCR            63     53        25    52    68    25    0.091
  Cybulski et al[@b8-ott-11-097]         2007   Poland    European    Prostate cancer   737/511        HB    RFLP-PCR            245    376       116   177   252   82    0.625
  Robbins et al[@b12-ott-11-097]         2008   USA       African     Prostate cancer   243/296        HB    iPLEX assay         183    55        5     225   66    5     0.951
  Shook et al[@b19-ott-11-097]           2007   USA       European    Prostate cancer   430/503        HB    TaqMan assay        187    183       60    221   225   57    0.981
  Shook et al[@b19-ott-11-097]           2007   USA       European    Prostate cancer   150/239        HB    TaqMan assay        72     62        16    136   96    7     0.039
  Shook et al[@b19-ott-11-097]           2007   USA       African     Prostate cancer   68/145         HB    TaqMan assay        45     13        10    111   31    3     0.633
  Daugherty et al[@b9-ott-11-097]        2008   USA       African     Prostate cancer   98/380         HB    TaqMan assay        73     23        2     277   98    5     0.261
  Daugherty et al[@b9-ott-11-097]        2008   USA       European    Prostate cancer   1,116/1,344    HB    TaqMan assay        463    505       148   554   602   188   0.237
  Nam et al[@b10-ott-11-097]             2010   Canada    Mixed       Prostate cancer   996/1,092      PB    MS                  477    409       110   521   459   112   0.463
  Nakazato et al[@b14-ott-11-097]        2003   Japan     Asian       Prostate cancer   101/105        HB    PCR                 69     32        0     71    26    8     0.021
  Wiklund et al[@b13-ott-11-097]         2004   Sweden    European    Prostate cancer   1,622/796      PB    TaqMan assay        597    778       247   297   384   115   0.627
  Rökman et al[@b26-ott-11-097]          2002   Finland   European    Prostate cancer   233/176        HB    Sequenom platform   88     106       39    69    84    23    0.745
  Shea et al[@b18-ott-11-097]            2008   USA       European    Prostate cancer   230/452        PB    RFLP-PCR            187    41        2     362   88    2     0.168
  Wang et al[@b17-ott-11-097]            2002   USA       European    Prostate cancer   918/493        PB    Sequenom platform   389    427       102   193   233   67    0.802
  Beuten et al[@b11-ott-11-097]          2010   USA       European    Prostate cancer   156/224        HB    PCR                 75     64        17    126   91    7     0.048
  Maier et al[@b16-ott-11-097]           2005   German    European    Prostate cancer   363/207        PB    PCR                 133    171       59    73    97    37    0.628

**Abbreviations:** SOC, source of control; HB, hospital-based; PB, population-based; RFLP-PCR, restriction fragment length polymorphism polymerase chain reaction; MS, mass spectrometry; PCR, polymerase chain reaction; HWE, Hardy--Weinberg equilibrium.

###### 

Results of meta-analysis for the RNASEL --1385G/A polymorphism and prostate cancer risks

  Study groups        N[\*](#tfn3-ott-11-097){ref-type="table-fn"}   G vs A                                                           GG vs GA   GG vs AA               GG/GA vs AA                                                                                                                                               
  ------------------- ---------------------------------------------- ---------------------------------------------------------------- ---------- ---------------------- ------------- ---------------------------------------------------------------- --------- ---------------------------------------------------------------- -------
  Total               16                                             0.964 (0.893--1.042)[‡](#tfn4-ott-11-097){ref-type="table-fn"}   0.029      1.009 (0.938--1.085)   0.973         0.854 (0.69--1.057)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    0.001     0.855 (0.703--1.040)[‡](#tfn4-ott-11-097){ref-type="table-fn"}   0.002
  Ethnicity                                                                                                                                                                                                                                                                                                                       
   Asian              1                                              1.40 (0.192--1.69)                                               0.116      1.14 (0.96--1.36)      0.057         1.265 (0.902--1.51)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    \<0.001   1.280 (0.098--1.65)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    0.001
   European           11                                             1.13 (0.60--1.97)                                                0.070      1.01 (0.73--1.51)      0.154         0.98 (0.69--1.37)[‡](#tfn4-ott-11-097){ref-type="table-fn"}      0.070     1.11 (0.76--1.52)[‡](#tfn4-ott-11-097){ref-type="table-fn"}      0.029
   African            3                                              0.787 (0.49--1.247)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    0.038      1.020 (0.760--1.368)   0.907         0.371 (0.176--0.783)                                             0.098     0.368 (0.175--0.776)                                             0.098
   Mixed              1                                              1.40 (0.192--1.69)                                               0.116      1.14 (0.96--1.36)      0.057         1.265 (0.902--1.51)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    \<0.001   1.280 (0.098--1.65)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    0.001
  SOC                                                                                                                                                                                                                                                                                                                             
   Hospital-based     11                                             0.908 (0.803--1.028)[‡](#tfn4-ott-11-097){ref-type="table-fn"}   0.013      0.985 (0.891--1.090)   0.866         0.697 (0.488--0.996)[‡](#tfn4-ott-11-097){ref-type="table-fn"}   0.000     0.701 (0.502--0.978)[‡](#tfn4-ott-11-097){ref-type="table-fn"}   0.001
   Population-based   5                                              1.40 (0.192--1.69)                                               0.116      1.14 (0.96--1.36)      0.017         1.265 (0.902--1.51)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    \<0.001   1.280 (0.098--1.65)[‡](#tfn4-ott-11-097){ref-type="table-fn"}    0.001

**Notes:**

*P*-value of *Q* test for heterogeneity test.

Studies of comparison.

Random model was used.

**Abbreviations:** SOC, source of control; OR, odds ratio; CI, confidence interval.
